While most of the advanced technologies already exist today, few pharmaceutical companies have yet to see any significant benefits. On one side, quality leaders struggle to define a clear business case for the technological changes, and thus fail to bring to management attention to the significant impact potential associated with lab digitization or automation. On the other side, companies often neglect the development of a clear long-term lab evolution strategy and blueprint, which can lead to some costly investments with unclear benefits.
— Read on https://www.pharmamanufacturing.com/articles/2018/the-future-of-quality-control/
Good overview of some current trends in QC labs.
Investigations of a Dog 